Healthcare
Live Price
Offline$21.28
-2.43% today
1Y Change
+83.57%
Window
Jun 27, 2025 → Jun 17, 2026
Coverage: 244 bars · Jun 27, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Jade Biosciences, Inc. (JBIO) is a Healthcare stock with a market cap of $780.00M and listed on NASDAQ. The stock last traded around $21.28 and up 83.6% across the available one-year price window (Jun 27, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +95.2%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +95.2%, free cash flow -33.3% with operating margin 0.0% and ROIC -28.1%. Stock Foundry combines JBIO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
JBIO
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
JBIO Max Drawdown
-44.21%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for JBIO and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$23.0M
+55.4% YoY
Free Cash Flow
-$27.6M
+29.9% YoY
Revenue Growth
+0.0%
EPS Growth
+95.2%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -26K | -282K | -96K | -68K | -15K |
| Operating Income | -114M | -75M | -81M | -53M | -23M |
| EBITDA | -114M | -69M | -75M | -51M | -23M |
| Net Income | -127M | -70M | -76M | -52M | -23M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 88M | 34M | 23M | 22M | 54M |
| Total Assets | 350M | 80M | 127M | 135M | 175M |
| Total Liabilities | 17M | 4M | 18M | 9M | 3M |
| Shareholder Equity | 333M | 76M | 109M | 127M | 172M |
| Total Debt | 724K | 417K | 675K | 1M | 574K |
| Net Debt | -88M | -33M | -23M | -21M | -54M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
27M
+30.0% YoY
Capital Expenditures
181K
+7.2% YoY
Free Cash Flow
28M
+29.9% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-64.6%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.